Jessica Skarzynski

FDA Approves Opdivo for the Frontline Treatment of Gastric Cancer

April 16, 2021

The FDA has approved the combination of Opdivo (nivolumab) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma, making it the first frontline immunotherapy agent approved in this space.